Vaisala reports its Q3/24 results on Thursday 24th of October.
19% ARR growth and 19% EBITDA margin, guidance raised again '25 guidance: ~13% ARR growth and 18-20%...
Redeye comments on I-Tech’s Q3 figures that posted solid growth of 27%, with healthy margins while E...
Sales -12% and adj. EBIT SEK -4m vs. ABGSCe Lower volumes from some large customers likely temporary...
Redeye provides a comment on Safeture’s Q3 2024 report, which showed ARR growth of 16% and sales gro...
Q3: EBITDA of NOK 12m vs. our NOK 10m, on lower costs Still relatively low visibility Estimates like...
Q3e: Two Freemelt ONE deliveries, sales SEK 9.3m, EBIT -24m Estimates down on slower-than-expected e...
Redeye is only making minimal changes to our forecasts on the back of the Q3 report.
Redeye updates its estimates ahead of Arise’s Q3 report which is due on 7 November.
Redeye updates its estimates and valuation following Vitec releasing its Q3 2024 report.
Ahead of Atria's Q3 report, we nudge up our estimates, owing to the warm autumn and the continued de...
Q3e: Medical stable, cyclical risk in Engineered Estimates lowered by 2% p.
Expect continued softness on orders, comps ease from Q4 Reduce '24e-'26e EBITA by 5-3% on delayed de...
Rec PTP -3% vs ABGSCe, driven by topline New swap agreements of ~SEK 835m Share to trade slightly be...
SRV publishes its Q3/24 figures on Thursday 24th of October.
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 16 oktober år 202...
Redeye initiates coverage of Elicera Therapeutics, a Swedish clinical-stage biotech company focusing...
Redeye provides its initial take on Vitec’s Q3 2024 report, which came in slightly below our estimat...
Profitability hampered by IAC in Scandpower Adj. EBIT margins to strengthen Negative revisions stem ...
Q3e: sales of SEK 50m (up 10%), EBIT of SEK 1.5m (-2.